Elan Investors OK $1B Buyback As Royalty Pharma Looms
The buyback effort won approval from 99 percent of the investors who voted at an extraordinary general meeting, convened to consider the plan. Shares were priced between $11 and $13 apiece, sticking by Thursday's $12 closing price.
Elan's stock repurchase is tied to a $3.25 billion-plus...
To view the full article, register now.